We provide patients with:

- the latest image-guided techniques for diagnosis and treatment
- an individualized treatment plan, comprehensive risk assessment, and long-term surveillance program
- access to innovative clinical trials of therapies, surgical techniques, and advanced technologies not available at other hospitals
- genomic sequencing, when indicated, to look for actionable mutations

KIDNEY CANCER PROGRAM OVERVIEW

MSK’s urologic cancer program is recognized as one of the world’s finest, ranked fifth out of 51 top-scoring hospitals for urology in U.S. News & World Report.

We provide patients with:

- the latest image-guided techniques for diagnosis and treatment
- an individualized treatment plan, comprehensive risk assessment, and long-term surveillance program
- access to innovative clinical trials of therapies, surgical techniques, and advanced technologies not available at other hospitals
- genomic sequencing, when indicated, to look for actionable mutations

LOCATIONS

Many of MSK’s specialists are centrally located in Manhattan. There are also MSK’s regional outpatient locations:

- MSK Basking Ridge, New Jersey
- MSK Bergen, New Jersey
- MSK Monmouth, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York
- MSK Westchester, New York

Our Team Leaders

Paul Russo, MD, FACS
Urologic Surgeon; Lead, MSK Kidney Surgery Program

Maria Carlo, MD
Medical Oncologist

Jonathan Coleman, MD
Urologist

Darren Feldman, MD
Medical Oncologist

A. Ari Hakimi, MD
Surgeon

Robert Motzer, MD
Jack and Dorothy Byrne Chair in Clinical Oncology

Karim A. Touijer, MD, MPH
Surgeon

Martin Voss, MD
Medical Oncologist

REFER A PATIENT

Contact the Physician Access Service directly at

800-525-2225

MSK has insurance contracts with most major health plans in the New York tristate area.

July 2018
Expertise

- Our specialists have expertise in different types of kidney cancer, including renal cell cancer and less common urothelial tumors in adults.
- Our surgeons are some of the most experienced in the world at performing radical nephrectomy, partial nephrectomy, and surgery for transitional cell tumors in the upper urinary tract.
- We offer comprehensive care for renal tumor patients, providing access to state-of-the-art surgical procedures and clinical trials for advanced cases.

Leadership

- We are one of the largest kidney cancer programs in the country, performing more than 540 surgeries per year for new cancers, including patients who are not considered to be surgical candidates elsewhere.
- Our surgical expertise in locally advanced and metastatic disease is globally recognized, including surgery involving the inferior vena cava and cytoreductive radical nephrectomy.
- Our surgeons participate in establishing the latest national guidelines for surgery and pre- and post-operative surgical care.
- We have more than 20 kidney cancer clinical trials underway for a range of targeted therapies, immunotherapies, and novel surgical approaches.
- Working with our world-class genetics program, our investigators are seeking clinical clues to improve the prognosis of kidney tumor patients.

Advanced Technologies

- We offer the full array of surgical approaches, selecting the open, laparoscopic or robotic-assisted procedure best suited to the patient. Our goal is to achieve the best oncologic outcomes while preserving renal function and quality of life.
- For select cases, we can analyze more than 400 cancer genes utilizing MSK-IMPACT™, a genome-sequencing test developed at MSK that can determine actionable mutations that may influence subsequent care.